Denmark - January 21, 2025
First Danish patients treated with gene therapy for haemophilia B
CSL Behring Denmark has announced that the first Danish patients with haemophilia B were treated with the gene therapy HEMGENIX (etranacogene dezaparvovec).
New Market - January 20, 2025
AstraZeneca’s Datroway approved in the US
First approval in the US for AstraZeneca and Daiichi Sankyo’s Datroway based on TROPION-Breast01 results showing 37% reduction in the risk of disease progression or death vs. chemotherapy.
Agreement - January 14, 2025
Synthego signs strategic licensing agreement with AstraZeneca
This agreement grants Synthego a global license to manufacture and distribute AstraZeneca's novel CRISPR gene editing enzyme, eSpOT-ON, recently published as engineered ePsCas9, to the worldwide research community.
Pharma - January 14, 2025
Xinnate receives Orphan Drug Designation from the FDA
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for the company’s drug candidate TCP-25 for the treatment of the severe disease Epidermolysis Bullosa (EB).
Financing - January 14, 2025
MONCYTE Health joins EUR 7 million project
MONCYTE Health has been selected to join a 4-year Horizon funded project as a core industrial partner.
Pharma - January 13, 2025
AstraZeneca’s datopotamab deruxtecan granted Priority Review in the US
AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) who have received prior systemic therapies, including an EGFR-directed therapy.
